YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
On September 22, Truist analyst Danielle Brill identified a "significant positive readthrough" for Maze Therapeutics, Inc. (NASDAQ:MAZE) following positive Phase 2 topline data from Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). The da…
Fresh Coverage Puts Maze Therapeutics in Focus Maze Therapeutics (MAZE) moved higher in pre-market trading on 23 September after CIBC began covering the clinical-stage kidney and metabolic disease specialist, with the share reaction unfold…
Vertex stock popped Tuesday — while shares of rival Maze Therapeutics skyrocketed — on a surprise expansion for their kidney disease drugs. Continue Reading
Maze Therapeutics stock jumped after Vertex Pharmaceuticals reported positive results for inaxaplin, boosting confidence in a rival treatment from Maze. Continue Reading
Harold Bernstein, President of Research and Development and Chief Medical Officer at Maze Therapeutics, Inc. (NASDAQ:MAZE), sold 9,705 shares of common stock on September 4, 2026, according to an SEC Form 4 filing. Transaction summary Metr…
Key Points CEO Jason Coloma sold 27,858 shares for a total value of approximately $725,000 across June 22 and June 23, 2026. This transaction involved Coloma's indirect holdings and reduced indirect ownership from 372,867 to 345,009 shares…
Jason V. Coloma, Chief Executive Officer of Maze Therapeutics (NASDAQ:MAZE), reported the indirect sale of 27,858 shares of common stock over three open-market transactions on June 22 and June 23, 2026, according to the SEC Form 4 filing.…
Jason Coloma, Chief Executive Officer of Maze Therapeutics(NASDAQ:MAZE), reported the sale of 32,564 common shares via multiple open-market transactions between May 22 and May 26, 2026, for a total consideration of approximately $847,000,…
On May 15, 2026, HighVista Strategies disclosed it sold 70,503 shares of Maze Therapeutics(NASDAQ:MAZE) in Q1 2026, an estimated $3.11 million trade based on quarterly average pricing. What happened According to a Securities and Exchange C…
* Maze Therapeutics press release [https://seekingalpha.com/pr/20512103-maze-therapeutics-reports-first-quarter-2026-financial-results-and-recent-highlights] (MAZE [https://seekingalpha.com/symbol/MAZE]): Q1 GAAP EPS of -$0.45 beats by $0.…
Atul Dandekar, Chief Strategy and Business Officer of Maze Therapeutics(NASDAQ:MAZE), reported the exercise and immediate sale of 7,500 shares of common stock for a transaction value of approximately $190,000 on April 29, 2026, as disclose…
Maze Therapeutics Inc. (NASDAQ:MAZE) is one of the 10 oversold small cap stocks to buy now. As of the April 24 closing, the consensus sentiment around the stock was strongly bullish. It received Buy ratings from all 12 analysts who provide…
Maze Therapeutics (MAZE [https://seekingalpha.com/symbol/MAZE]) has priced [https://seekingalpha.com/pr/20482399-maze-therapeutics-announces-150-million-registered-offering]its underwritten registered offering of 5.54M shares of its common…
(RTTNews) - Maze Therapeutics, Inc. (MAZE), a clinical-stage biopharmaceutical company, on Wednesday, announced the pricing of an underwritten registered offering of stock and pre-funded warrants expected to raise approximately $150 millio…
SOUTH SAN FRANCISCO, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE) today announced the pricing of its underwritten registered offering of 5,540,000 shares of its common stock at a price of $23.50 per sha…
We recently compiled a list of the 8 Oversold Biotech Stocks to Invest In Now. Maze Therapeutics, Inc. is one of the oversold stocks on our list. TheFly reported on April 14 that Truist Securities maintained its Buy rating on MAZE while re…
Maze Therapeutics, Inc. (NASDAQ:MAZE) is one of the 8 Most Oversold Strong Buy-Rated Stocks to Invest In. On March 31, 2026, JPMorgan raised the price target on Maze Therapeutics, Inc. (NASDAQ:MAZE) to $58 from $52 and maintained an Overwe…
Key Points Chief Medical Officer Harold Bernstein sold 15,000 company shares for a transaction value of ~$442,000 at around $29.46 per share on April 1, 2026. This disposition represented 100% of Harold Bernstein's direct Common Stock hold…
Harold Bernstein, President, R&D & CMO of Maze Therapeutics(NASDAQ:MAZE), reported the exercise of 15,000 stock options and immediate sale of the corresponding common shares for a total value of approximately $736,000 according to the SEC…
Maze Therapeutics (MAZE) said Wednesday its experimental oral medication demonstrated a 35.6% averag PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
[An arrow pointing downwards on top of a pile of US dollar bills.] Maze Therapeutics (MAZE [https://seekingalpha.com/symbol/MAZE]) plunged ~37% on Wednesday despite reporting encouraging initial data from a Phase 2 trial for its lead asset…
Maze Therapeutics stock crashed Wednesday despite "overwhelmingly positive" test results for a kidney disease drug. Continue Reading
(RTTNews) - Biopharmaceutical company Maze Therapeutics, Inc. (MAZE) announced Wednesday positive topline data from the Phase 2 HORIZON trial of MZE829, an oral, small molecule, dual-mechanism APOL1 inhibitor, in patients with broad APOL1-…
Maze Therapeutics, Inc. Positive topline data from Phase 2 HORIZON trial of MZE829 demonstrating first clinical proof-of-concept in patients with broad AMKD to support advancement into pivotal program; Maze to host conference call today at…
Key Points One of Maze Therapeutics' executives exercised and sold 30,000 shares on March 10, 2026, generating gross proceeds of ~$1.51 million at a weighted-average price of ~$50.45 per share. Bernstein retains 267,407 shares in stock opt…
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Truist upgraded Block (XYZ) to Buy from Ho…
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top Upgrades: TD Cowen upgraded Rivian (RIVN) to Buy from…
The chronic kidney disease market growth is being driven by the rising global prevalence of diabetes, hypertension, and aging populations. Increasing awareness and earlier diagnosis are expanding the pool of patients eligible for treatment…
What happened According to its SEC filing dated February 17, 2026, a16z Capital Management, L.L.C. established a new position in Navan(NASDAQ:NAVN) by acquiring roughly 27 million shares during the fourth quarter. The estimated transaction…
Key Points Acquired 27,195,364 shares of Navan; estimated trade size $464.50 million (based on quarterly average pricing) Quarter-end position value increased by $464.50 million, reflecting the addition of the new position The new NAVN pos…
Amy Bachrodt, SVP, Finance of Maze Therapeutics(NASDAQ:MAZE), exercised 5,000 options and immediately sold the underlying common shares on Jan. 22, 2026, for a total transaction value of approximately ~$227,612, according to a SEC Form 4 f…
Key Points A Maze insider recently exercised 72,500 shares and then immediately sold them for an aggregate transaction value of approximately $2.94 million. As such, the shares originated from option exercises that were fully vested and im…
SOUTH SAN FRANCISCO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases…
First-in-human data from Phase 1 trial of MZE782 support best- and first-in-class potential; two Phase 2 proof-of-concept trials in phenylketonuria (PKU) and chronic kidney disease (CKD) expected to initiate in 2026 Enrollment ongoing in P…
(RTTNews) - Risk runs high, but so does the upside. Biotech investing thrives on bold bets and breakthrough data. On October 30, 2025, a wave of clinical-stage and commercial biopharma stocks surged to new 52-week highs, driven by breakthr…
SOUTH SAN FRANCISCO, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases…